Paper
0
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Authors
Nikhil Munshi,Larry Anderson
Nina Shah,Deepu Madduri,Jesús Berdeja,Sagar Lonial,Noopur Raje,Yi Lin,David Siegel,Albert Oriol,Philippe Moreau,Ibrahim Yakoub‐Agha,Michel Delforge,Michèle Cavo,Hermann Einsele,Hartmut Goldschmidt,Katja Weisel,Alessandro Rambaldi,Donna Reece,Fabio Petrocca,Monica Massaro,Jamie Connarn,Shari Kaiser,Payal Patel,Liping Huang,Timothy Campbell,Kristen Hege
+25 authors
,Jesús MiguelPublished
Feb 24, 2021
Show more
Save
Tip0
TipSave
Abstract
Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.